Edmonton, Alberta, Canada/January 17, 2023 - Pacylex Pharmaceuticals, a clinical-stage company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, announced the appointment of Michele Libonati to the role of Chief Operating Officer (COO). In this new role, Ms. Libonati will oversee Pacylex's day-to-day operations, including preclinical and clinical development, program management, and strategic and administrative functions. Ms. Libonati will report to Michael Weickert, Ph.D., Chief Executive Officer of Pacylex.
To view the full announcement, including downloadable images, bios, and more, click here.
- New executive team members expand general management and clinical operations expertise.
- PCLX-001 is currently being evaluated for safety and tolerability in patients with relapsed/refractory Non-Hodgkin Lymphoma (NHL) and in patients with solid tumors, with an expansion study starting in Q1 2023.
- Clinical investigation of PCLX-001 in patients with Acute Myeloid Leukemia (AML) is expected to begin in Q2 2023.
Click image above to view full announcement.
About Pacylex Pharmaceuticals
Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with a first-in-class oral once daily therapeutic, PCLX-001. Pacylex has a US Subsidiary in the San Francisco Bay area. PCLX-001 is the lead drug in a new class of N-myristoyltransferase (NMT) inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex is conducting a Phase 1 dose escalation study in Canada in patients with non-Hodgkin lymphoma and solid tumors (ClinicalTrials.gov Identifier: NCT04836195). The FDA cleared the IND for PCLX-001 for a Phase 1/2 clinical study in patients with acute myeloid leukemia (AML) planned to start in Q2 2023. The FDA also granted PCLX-001 both Orphan Drug Designation and Fast Track Designation for AML. Pacylex received support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation. The US Department of Defense is supporting the initial clinical investigation of PCLX-001 in AML patients. For additional information, please visit www.pacylex.com.
Contacts:Pacylex Pharmaceuticals: Michael J. WeickertCEO, Pacylex Pharmaceuticals, Inc.E: email@example.comP: 650-218-1840Twitter @Pacylex (https://twitter.com/pacylex) LinkedIn (www.linkedin.com/company/pacylex-pharma)Facebook (https://www.facebook.com/pacylex)Reportable page:( https://pacylex.reportablenews.com/ )#cancer, #lymphoma, #leukemia, #albertacancer, #Pacylex, #PCLX001, #UAlberta; #UAlberta_FoMD; #Worldslongestgame, #ASH22, #MDACC, #AML
Michael Weickert Ph.D
Distributed by: Reportable, Inc.